Translational Medicine

An increasingly important biomedical speciality

Webinars, events, articles and multi-media lectures

Back

Hannah Morgan

Senior Principle Scientist

Novartis Pharma AG Translational Medicine

As a Senior Principal Scientist in the translational immunology group in pre-clinical safety (PCS) Dr. Hannah Morgan is a specialist in the in vitro assessment of biotherapeutic-induced immune related adverse events with a particular focus on immunogenicity.

She completed her PhD in molecular neuroscience at University College London in 2009, and subsequently joined Novartis. She supports in vitro immunogenicity assessments with the development of dendritic cell based assays to assist in both candidate design and mechanistic root cause investigations. She also sits in internal expert teams offering consultancy and training on the subject of immunogenicity. In addition, she has been actively involved in external collaborations including the Innovative Medicine Initiative sponsored consortia, ABIRISK and ImSAVAR.

Webinars, events, articles and multi-media lectures

Sign up to hear from us:

CONTACT US
Ruskin House, 40-41 Museum Street, London WC1A 1LT, UK

Henry Stewart Conference Studies LLP is a limited liability partnership, registered in England, registration number OC334769 with its registered office at 40-41 Museum Street, London WC1A 1LT. Henry Stewart Events Ltd is a limited company, registered in England, registration number 06532399 with its registered office at 40-41 Museum Street, London WC1A 1LT. Henry Stewart Events, Inc. is a corporation incorporated in the State of Delaware, USA having a business office at PKF O’Connor Davies LLP, 665 Fifth Avenue, New York NY 10022.
© Henry Stewart Conference Studies LLP or its affiliates.